Therion Biologics Licenses LFA-3 Patent Rights from Biogen Idec Inc.

Strategic Insights

Jan 18, 2004 — 1 min read

Therion Biologics Corporation has announced the licensing of patent rights related to lymphocyte function associated antigen-3 (LFA-3) from Biogen Idec Inc. This licenses adds to Therion's intellectual property portfolio, strengthening its proprietary position in advancing its lead cancer vaccine candidates, Prostvac-VF and Panvac-VF. The agreement allows Therion to develop, manufacture, and commercialize oncology product candidates incorporating the LFA-3 co-stimulatory molecule in exchange for an upfront licensing fee, milestone payments, and royalties based on potential product sales.

Key Takeaways:

Therion Biologics Corporation has licensed patent rights related to lymphocyte function associated antigen-3 (LFA-3) from Biogen Idec Inc.
LFA-3 is a component of TRICOM, Therion's co-stimulatory system for optimizing immune response against tumor cells.
TRICOM is an integral component of Therion's proprietary lead cancer vaccine candidates, Prostvac-VF and Panvac-VF, currently in clinical investigation for metastatic prostate cancer and pancreatic cancer, respectively.
The addition of LFA-3 patent rights to Therion's intellectual property portfolio strengthens its proprietary position.
The agreement includes an upfront licensing fee, milestone payments, and royalties based on potential product sales.
TRICOM uses three co-stimulatory molecules: ICAM-1, B7.1, and LFA-3, to enhance antigen presentation and activation of immune responses critical for tumor destruction.
Therion is using TRICOM as part of its pox virus vector-based approach to cancer immunotherapy for prostate, pancreatic, and other cancers.
Therion Biologics Corporation develops therapeutic vaccines for cancer and preventive vaccines for AIDS.

Statistics:

Prostvac-VF is currently in a phase II clinical trial for the treatment of metastatic prostate cancer.
Panvac-VF is planning to begin a phase II trial in pancreatic cancer in early 2004.
The upfront licensing fee, milestone payments, and royalties details of the agreement were not disclosed.

Sources:

NewsRx.com & NewsRx.net
Biogen Idec Inc. (NASDAQ:BIIB)
Therion Biologics Corporation

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients